The Metabolic Triple Threat
The "Metabolic Triple Threat" in Oncology Subject: Repurposed Compounds (FECO, Fenbendazole, Ivermectin) Date: February 2026 Objective: To summarize the preclinical and emerging clinical evidence regarding the synergistic mechanisms of these compounds against malignant cell lines. 🛑 Clinical DisclaimerThis document is for educational and informational purposes only. These compounds are currently considered "off-label" for cancer treatment. This summary is intended to facilitate a discussion between a patient and their oncology team. It does not constitute medical advice or a treatment protocol. 1. FECO (Full Extract Cannabis Oil)Primary Mechanism: Signal Transduction & ApoptosisThe "Entourage Effect": Unlike isolated CBD/THC, FECO contains a full spectrum of cannabinoids and terpenes that act synergistically. Pathway Modulation: Recent studies (Frontiers in Pharmacology, 2025) show that FECO can inhibit the PI3K/AKT/mTOR pathway, a major driver of cell survival and proliferation. Apoptosis: Activates CB1 and CB2 receptors to trigger "ER Stress," forcing cancer cells into programmed cell death while sparing healthy cells. 2. Fenbendazole (Benzimidazole Class) Primary Mechanism: Structural Integrity & Glucose Metabolism Microtubule Inhibition: Acts as a moderate microtubule-destabilizing agent. It binds to tubulin, preventing the "scaffolding" required for cancer cell division (Nature Scientific Reports, 2018). Metabolic Starvation: Downregulates GLUT transporters and Hexokinase II, effectively blocking the cell’s ability to process glucose—the primary fuel source for many tumors (The Warburg Effect). Pyroptosis: New data (2025) suggests it may trigger pyroptosis, a form of cell death that alerts the immune system to the presence of the tumor. 3. IvermectinPrimary Mechanism: Stem Cell Signaling & Efflux InhibitionWnt/β-catenin Pathway: Inhibits the signaling pathway responsible for cancer stem cell self-renewal and metastasis (Drug Design, Development and Therapy, 2020). Blocking "Escape Routes": Inhibits P-glycoprotein (MDR1). This prevents the cancer cell from "pumping out" therapeutic agents, potentially reversing multi-drug resistance. Mitochondrial Stress: Induces mitochondrial dysfunction and oxidative stress specifically within the tumor microenvironment. 💡 The Synergistic RationaleWhen combined, these three agents theoretically address the "Hallmarks of Cancer" from three distinct angles: CompoundTarget AreaTheoretical Benefit FECOCell SignalingTriggers the "Off" switch (Apoptosis). Fenbendazole Cellular Structure Destroys the "Skeleton" and cuts off fuel (Glucose). Ivermectin Defense Mechanisms Blocks the "Pumps" and stops the spread (Metastasis). Key Peer-Reviewed References for Discussion Dogra et al. (2018): Fenbendazole acts as a microtubule destabilizing agent. (Scientific Reports)Frontiers in Pharmacology (2025): Cannabis derivatives and PI3K/AKT
